Biotron Limited (AU:BIT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biotron Limited reported mixed results from its Phase 2 COVID-19 trial for the antiviral drug BIT225, which met safety and tolerability endpoints but not efficacy targets. Despite this, Biotron continues to advance its research on antiviral compounds, including promising developments in HIV-1 and Dengue virus programs. The company remains committed to exploring commercial opportunities for its unique viroporin antagonist platform, which shows broad-spectrum antiviral activity.
For further insights into AU:BIT stock, check out TipRanks’ Stock Analysis page.